Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers.

Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, Almendro V, Russnes H, Børresen-Dale AL, Levine AJ, Bhanot G, Ganesan S.

PLoS One. 2012;7(6):e38575. doi: 10.1371/journal.pone.0038575. Epub 2012 Jun 13.

2.

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.

Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M.

BMC Cancer. 2006 Oct 13;6:245.

3.

Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.

Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, Lee JE, Shin HJ, Hwang KT, Hwang SE, Kim SW, Noh DY.

BMC Cancer. 2006 Apr 12;6:92.

4.
5.

Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease.

Helms MW, Kemming D, Pospisil H, Vogt U, Buerger H, Korsching E, Liedtke C, Schlotter CM, Wang A, Chan SY, Brandt BH.

Br J Cancer. 2008 Sep 2;99(5):774-80. doi: 10.1038/sj.bjc.6604556. Epub 2008 Aug 12.

6.
7.

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L.

J Clin Oncol. 2010 Oct 1;28(28):4316-23. doi: 10.1200/JCO.2009.27.2419. Epub 2010 Aug 30. Erratum in: J Clin Oncol. 2010 Nov 10;28(32):4868. J Clin Oncol. 2012 Feb 20;30(6):679.

PMID:
20805453
8.

A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.

Miller PC, Clarke J, Koru-Sengul T, Brinkman J, El-Ashry D.

Clin Cancer Res. 2015 Jan 15;21(2):373-85. doi: 10.1158/1078-0432.CCR-14-2053. Epub 2014 Nov 4.

9.

A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.

Szekely B, Iwamoto T, Szasz AM, Qi Y, Matsuoka J, Symmans WF, Tokes AM, Kulka J, Swanton C, Pusztai L.

Breast Cancer Res Treat. 2013 Apr;138(3):691-8. doi: 10.1007/s10549-013-2475-4. Epub 2013 Mar 17.

PMID:
23504136
10.

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM.

Ann Oncol. 2012 Nov;23(11):2866-73. doi: 10.1093/annonc/mds080. Epub 2012 Apr 24.

11.

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S.

Breast Cancer Res Treat. 2012 Feb;131(3):881-90. doi: 10.1007/s10549-011-1482-6. Epub 2011 Apr 19.

PMID:
21503684
12.

Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.

Hoppe R, Achinger-Kawecka J, Winter S, Fritz P, Lo WY, Schroth W, Brauch H.

Eur J Cancer. 2013 Nov;49(17):3598-608. doi: 10.1016/j.ejca.2013.07.145. Epub 2013 Aug 19.

PMID:
23968733
13.

Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers.

Yau C, Wang Y, Zhang Y, Foekens JA, Benz CC.

Breast Cancer Res Treat. 2011 Apr;126(3):803-10. doi: 10.1007/s10549-011-1345-1. Epub 2011 Jan 12.

14.

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.

Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F.

BMC Cancer. 2008 Nov 21;8:339. doi: 10.1186/1471-2407-8-339.

15.

Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.

Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G.

Clin Cancer Res. 2016 Jan 15;22(2):337-45. doi: 10.1158/1078-0432.CCR-15-0757. Epub 2015 Sep 30.

16.

Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.

Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L.

Clin Cancer Res. 2011 Apr 15;17(8):2591-601. doi: 10.1158/1078-0432.CCR-10-1045. Epub 2011 Jan 19.

17.

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA, Chetty U.

Breast Cancer Res. 2010;12(4):R47. doi: 10.1186/bcr2604. Epub 2010 Jul 8.

18.

A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation.

Zhou X, Li B, Zhang Y, Gu Y, Chen B, Shi T, Ao L, Li P, Li S, Liu C, Guo Z.

Breast Cancer Res Treat. 2013 Dec;142(3):505-14. doi: 10.1007/s10549-013-2767-8. Epub 2013 Nov 20.

PMID:
24253811
19.

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.

Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C.

BMC Genomics. 2008 May 22;9:239. doi: 10.1186/1471-2164-9-239.

20.

RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.

Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO.

Breast Cancer Res Treat. 2011 Jul;128(2):315-26. doi: 10.1007/s10549-010-1073-y. Epub 2010 Aug 10.

PMID:
20697807

Supplemental Content

Support Center